Bio-Path Holdings, Inc., (BPTH), is a clinical stage biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs. Following the successful completion of the safety testing in Stage 2 of a Phase 2 Clinical Trial of prexigebersen in Acute Myeloid Leukemia (AML), Bio-Path is advancing this program to its next stage in the first half of 2020. In addition, Bio-Path filed an IND application for prexigebersen in the treatment of solid tumors including ovarian and endometrial cancer and expect to start that study later in 2020. Bio-Path is initiating a Phase 1 study of its 2nd pipeline candidate, BP1002 (liposomal Bcl-2), in the 1st half of 2020 to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. And BioPath is nearing completion of IND-enabling studies of BP1003, a novel liposome- incorporated STAT3.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
prexigebersen (liposomal Grb2)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):